BF Biosciences Limited has launched Zeptide® (Tirzepatide) a next-generation treatment for Type 2 diabetes and obesity in Pakistan, marking a significant advancement in the local biotech sector.
Zeptide® is a dual-agonist medication that activates both GLP-1 and GIP receptors, offering a pioneering mechanism in managing blood sugar levels and reducing weight. Manufactured in Pakistan at BF Biosciences’ facility, the product comes in a ready-to-use prefilled syringe format designed for improved dosing accuracy and patient safety.
The company emphasizes that Zeptide® meets international quality standards, having passed rigorous testing both in the United States and in Pakistan. This launch supports BF Biosciences’ broader strategy of reinvesting IPO proceeds into local healthcare infrastructure and expanding its portfolio of biologic therapies.
With Pakistan facing one of the world’s highest burdens of diabetes and rising obesity rates including over nine million undiagnosed diabetic individuals and large portions of the population classified as overweight — the introduction of Zeptide® arrives at a critical juncture for public health
